Background New ACR/EULAR classification criteria for RA were developed in response to the criticism of existing 1987 ACR criteria due to insufficient sensitivity in early disease. According the new criteria a score of ≥6 is indicative of the presence of RA. But one limitation of these new criteria is a lack of factors with imaging techniques for a better identification of patients with high-risk to devolope erosive course.
Objectives There are two other prediction models for development of RA, the Helm-van Mil-Score without imaging techniques and the Visser-Score with detection of early erosions by X-ray. The calculated scores correspond to the probability of persistent or self-limiting and non-erosive or erosive course. The aim was to compare the new ACR/EULAR criteria with two other long existing predictive scores regarding cut-off for erosive course.
Methods 95 Patients with early arthritis were observed and classified by new ACR/EULAR criteria, Helm-van Mil-Score (HvM) and Visser-Score. The treatment decision was made by subjective assessment of the severity. 35 patients have ACR/EULAR-Score ≥6, 33 patients have HvM-Score ≥8 (positive prediction of persistence 84%) and 27 patients with a prediction of persistence ≥80% measured by Visser-Score. All patients will be monitored in order to differentiate in the course by over-treated and under-treated regarding different prediction scores.
Results There are differences in prediction values for many patients with undifferentiated Arthritis. The pictures show the different cut-offs for assessing the persistence of arthritis. According to the ACR/EULAR criteria, 35 patients a treatment would be supplied with DMARDs, according to Helm-van Mil 33 and after Visser score only 27. It should be clarified in the course of the investigation which patients benefit from treatment actually.
Conclusions There is a difference of 8 patients between ACR/EULAR criteria of RA and theultrasound-assistedVisser-Score. The at least one year follow up will show how many patients develop a RA and how many of them need an early anti-inflammatory therapy with DMARDs. The goal is to treat as many patients as early as adequate, while the number of over-treated patients on low to keep.
Disclosure of Interest None Declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.